Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

CaaS Capital Management

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 12
Average round size
The average size of a deal this fund participated in
Portfolio companies 12
Rounds per year 4.00
Lead investments 0
Exits 3
Key employees Soon
Stages of investment
Late Stage Venture

Areas of investment

  • Biotechnology
  • Biopharma
  • Pharmaceutical
  • Health Care
  • Therapeutics

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of CaaS Capital Management:
Typical Co-investors
CaaS Capital Management is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after CaaS Capital Management:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Allianz Bayern, Germany, München
Association and Startup Accelerator New York, New York, United States
Brookfield Renewable Partners Canada, Hamilton, Ontario
Centerman Capital -
Charter Capital Partners Grand Rapids, Michigan, United States
Chowdry Associates -
Dalai Lama Foundation California, Redwood City, United States
FedNor -
FIEGE Germany, Greven, Nordrhein-Westfalen
Irish Research Council(IRC) Ballsbridge, Dublin, Ireland
Livonia Partners Latvia, Riga, Vidzeme
MTC Group -
Plantec Consulting Japan, Tokyo
Plug N Play New York, United States, Valley Cottage
PremjiInvest Bangalore, India, Karnataka
San-in Godo Bank Japan, Matsue, Shimane Prefecture
Shaw and Partners Australia, New South Wales, Sydney
Tencent Music Entertainment China, Guangdong, Shenzhen
Tracxn Syndicate Bangalore, India, Karnataka
Virgo Investment Group California, Redwood Shores, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Solid Biosciences

Health Care
$75M30 Sep 2022 Marlborough, Massachusetts, United States

Ventyx Biosciences

$176M19 Sep 2022 Encinitas, California, United States

2seventy bio

$170M16 Mar 2022 -

HotSpot Therapeutics

Health Care
Life Science
$100M29 Nov 2021 Cambridge, Massachusetts, United States


$110M02 Aug 2021 Berlin, Berlin, Germany

Artios Pharma

Medical Device
$150M27 Jul 2021 Cambridge, England, United Kingdom

Turnstone Biologics

Innovation Management
$80M14 Jul 2021 San Francisco, California, United States

Umoja Biopharma

Developer Platform
Information Technology
$210M15 Jun 2021 Seattle, Washington, United States


Health Care
$115M13 Apr 2021 Maryland, United States
T-knife Therapeutics Closes $110M Series B Financing

– T-knife Therapeutics, Inc. from Berlin, Germany develops T-cell receptor (TCR) therapeutics for solid tumor patients.
– Company completed a $110m Series B financing.
– The round was led by Fidelity Management & Research Company, LLC., with participation from other new investors including LSP, Qatar Investment Authority (QIA), Casdin Capital, Sixty Degree Capital, and CaaS Capital, along with existing investors RA Capital Management, Versant Ventures and founding investor Andera Partners.
– The new investment will be used to expand the company’s scientific team, increase manufacturing capacity and advance its pipeline of TCR-T.

Turnstone Biologics Raises $80 Million Series D Financing

– Turnstone Biologics Corp. announced the successful completion of an $80m Series D financing co-led by PFM Health Sciences and Point72.
– New investors include Eventide Asset Management, Surveyor Capital (a Citadel company), Ridgeback Capital Investments, Takeda Ventures, CaaS Capital, JM Family Enterprises, Inc., Northleaf Capital Partners, 404 Bio and an undisclosed investor.
– The round was joined by existing investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.
– Proceeds from the financing will be used to advance Turnstone’s pipeline of programs from its oncolytic virus and TIL therapy platforms.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent CaaS Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: